Results 111 to 120 of about 104,468 (145)

Use of Fibrin Sealant in Pediatric Orbital Fracture Repair. [PDF]

Plast Reconstr Surg Glob Open
Humphrey JG, Laguerre W, Sarpong C, Means O, Komorowska-Timek E.   +4 more
europepmc   +1 more source

Integration of lymphatic vasculature to a human lymph node-on-chip enhances physiological immune properties

Morrison AI, Jäger J, de Winde CM, Roest HP, Laan LJvd, Gibbs S, Koning JJ, Mebius RE.   +7 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Aprotinin

Annals of Pharmacotherapy, 1996
OBJECTIVE: To review the clinical pharmacology of aprotinin in patients undergoing surgical procedures involving major blood loss, namely, coronary artery bypass graft (CABG). DATA SOURCES: A MEDLINE search was used to identify French-and English-language publications on aprotinin using the indexing terms aprotinin, cardiothoracic surgery, and ...
S, Robert, B K, Wagner, M, Boulanger, M, Richer   +3 more
openaire   +2 more sources

Aprotinin

European Journal of Anaesthesiology, 2015
SCOPUS: re.j ; info:eu-repo/semantics ...
De Hert, Stefan, Van Der Linden, Philippe, Von Heymann, Christian, Gill, Ravi, Habre, Walid, Lancé, Marcus, Llau, Juan J.V., Meier, Jens, Pouard, Philippe, Samama, Charles Marc, Van Der Linden, Jan   +10 more
openaire   +5 more sources

Aprotinin: is it prothrombotic?

Perfusion, 2001
Controversy continues as to whether aprotinin (Trasylol) is prothrombotic. The recent discovery of the thrombin receptor family, known as the protease-activated receptor family (PAR) has been essential in aiding our understanding of the mechanism of action of aprotinin.
Michael Poullis, R C Landis, Kenneth M. Taylor   +2 more
openaire   +3 more sources

Expression, purification and characterization of aprotinin and a human analogue of aprotinin

Protein Expression and Purification, 2009
Aprotinin is a Kunitz-type inhibitor with a relatively broad specificity. It has been shown to be clinically useful for the management of hemorrhagic complications. In this report, small ubiquitin-related modifier (SUMO) linked with a hexa-histidine tag was used as a fusion partner for the production of recombinant aprotinin and a human aprotinin ...
Fengyuan Tang, Ziyong Sun, Jian-Ning Liu, Jian-Ning Liu, Aiqing Jiang, Junyong Chen, Wei Lu   +6 more
openaire   +3 more sources

Aprotinin for intraoperative haemostasis

Neurosurgical Review, 1981
Because of the special anatomical conditions of neurosurgery, the success of any operation depends on accurate haemostasis. This paper reports on an additional measure for the achievement of intraoperative haemostasis which has been successfully used during more than 1200 neurosurgical interventions. Meninges and cerebral tissue contain relatively high
D. Giromini, T. Tzonos
openaire   +3 more sources

Aprotinin and renal dysfunction

Expert Opinion on Drug Safety, 2008
Aprotinin is a polypeptide serine protease inhibitor used to prevent bleeding and need for transfusions in patients having heart surgery. A recent analysis of an observational study data set suggested the use of aprotinin was associated with an increased risk of developing renal failure.
David Royston, Marie Bosman
openaire   +3 more sources

Aprotinin in cardiac surgery

Expert Review of Cardiovascular Therapy, 2006
Aprotinin is a naturally occurring serine protease inhibitor that is being used with increasing frequency in cardiac surgery and beyond to reduce blood loss and the need for perioperative blood transfusion. Through inhibition of serine proteases such as plasmin, aprotinin significantly reduces fibrinolysis, thereby aiding hemostasis during surgical ...
Munir Boodhwani, Basel Ramlawi, Neel R. Sodha, Cesario Bianchi, Frank W. Sellke   +4 more
openaire   +3 more sources

Aprotinin: A Pharmacologic Overview

Orthopedics, 2004
abstractAprotinin is a polypeptide with serine protease inhibitory activity of key enzymes associated with inflammatory, fibrinolytic, and hemostatic pathways. The drug binds directly to the fibrinolytic plasmin at the lower plasmin-inhibiting dose (plasma concentration, 137 KlU/mL), and the inflammatory mediator, kallikrein, using the higher ...
Edward Sypniewski, Jerrold H. Levy
openaire   +3 more sources